Virtual Library
Start Your Search
T. Umeno
Author of
-
+
P3.08 - Poster Session/ Thymoma, Mesothelioma and Other Thoracic Malignancies (ID 226)
- Event: WCLC 2015
- Type: Poster
- Track: Thymoma, Mesothelioma and Other Thoracic Malignancies
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P3.08-013 - Twenty-Four Cases of Malignant Pleural Mesothelioma in Iwakuni, Japan (ID 981)
09:30 - 09:30 | Author(s): T. Umeno
- Abstract
Background:
Asbestos had been stopped to use in Japan since the late 1970s. Asbestos exposure will increase the risk of mesothelioma and the interval between initial exposure and subsequent biological consequences is assumed more than 40 years. Iwakuni is part of the Seto Inland Sea industrial area and one of the oldest petrochemical industrial complexes in Japan is located. The incidence of mesotheliomas is expected to rise over the next decade. Treatment for mesothelioma includes surgery, chemotherapy, radiation therapy and their combination. Recently, cisplatin in conjunction with pemetrexed has shown advantageous results in reducing tumors, but pleural mesothelioma is still incurable fatal disease except specific case. In this study, we reviewed the clinical features of 26 patients with malignant pleural mesotelioma treated in our institute.
Methods:
Between January 2006 and December 2014, 26 patients were histologically diagnosed as malignant pleural mesotelioma. Retrospective review was performed and demographic, clinical, pathologic, treatment and survival data were collected. Overall survival were estimated by the Kaplan-Meier analysis. Surgery includes two patients treated by trimodality therapy (chemotherapy + extrapleural pneumonectomy + radiation therapy) and a patient treated by pleurectomy combined with hyperthermic therapy. Other four patients were treated by extrapleural pneumonectomy alone.
Results:
In the studied population,21 of 26 patients were male.the mean age of diagnosis was 72y.Each number of histological subtypes(epithelial,sarcomatoid and biphasic) were 15,6,and 5.The number of patients who treated with surgery were 8,with chemotherapy were 17 and best supportive care was 1. The median survival time of the 27 malignant pleural mesotelioma patients was 13.4 months. According to histological subtypes,the MTS of epithelial,sarcomatoid and biphasic were 21.4 months,6.5 months and 11.6 months The MTS of surgery and chemotherapy were 21.4 months and 13.2 months.One year survival rate were 85.7% and 47.6%. The MTS of the patients with and without pleural plaque were 13.4 months and 15.0 months. Female gender, epithelial subtypes, treatment of surgery and patients without pleural plaque showed relatively favorable outcome.
Conclusion:
Because of the appearance of effecrive chemotherapies,such as Pemetrexed sodium hydrate,better survival has been observed in patients treated by chemotherapy. However, long-term survival was seen only in patients treated by surgery. Surgery allows us to accurately stage patients and provide data that may be useful in better patient stratification. Surgery should be selected for the operable patients with c-stage I-II and epithelial disease. We have to detect malignant pleural mesothelioma in early stage and treat in appropriate means.
